Pipeline Insight: Prostate Cancer - Domination By The Innovative Classes

Introduction:

Prostate cancer, the most prevalent cancer for men, is a very large and very competitive market. The anti-androgen and LHRH analog drug classes currently dominate the market. With the development of a number of innovative therapies from new pharmaceutical companies entering the market for the first time, the prostate cancer market is about to enter a more dynamic and high growth phase. 

Scope:

* Analysis of late-stage pipelines: anti-hormonals, cytotoxics, and innovatives, with sales forecasts to 2011; plus overview of early-stage innovatives 

* Patient potential, highlighting trends in incidence, prevalence and diagnosis of prostate cancer 

* Analysis of the global prostate cancer market, identifying key market and treatment trends 

* Case studies featuring the leading global players: AstraZeneca, Abbott and TAP Pharmaceuticals 

Report Highlights:

Innovative drugs have made their mark in the prostate cancer pipeline but this does not guarantee good uptake among physicians 

More drugs are in development for the greatest unmet need in prostate cancer 

Prevalence of prostate cancer at over 2m in 2003 in the seven major markets 

Reasons to Purchase:

* Characterize saturated and under-served markets in Prostate Cancer. Are the anti-hormonals still an attractive class? 

* Identify the key unmet needs in Prostate Cancer - will the innovatives group satisfy them? 

* Find potential out-licensing and co-marketing partners in the Prostate Cancer market 

Publisher: Datamonitor Oncology Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Oncology.html#a264